Phase II Trial of Gefitinib in Combination With Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer With Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Journal of Thoracic Oncology - United States
doi 10.1097/jto.0000000000000434
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2015
Authors
Publisher
Elsevier BV